News | June 17, 2008

FDG-PET Highlights Stimulant’s Role in Brain Function Deterioration

June 18, 2008 - Concerned by the growing numbers of people using stimulant medications such as methylphenidate (MP)—either legally or illegally—to improve attention and focus, researchers used positron emission tomography (PET) imaging with the radiotracer fluorodeoxyglucose (FDG) to assess the effects of the drug on brain function in the normal human brain.
“MP is often prescribed appropriately for individuals with attention deficit hyperactivity disorder (ADHD), who are unable to focus their minds in order to perform everyday tasks,” said Nora Volkow, M.D., director of the National Institute of Drug Abuse in Bethesda, Md. “We wanted to better understand how the drug works in ‘normal, healthy’ people when they are performing a cognitive task, as well as when they are not.”
The study comprised 23 healthy adults, who were tested at baseline and while performing an accuracy-controlled cognitive task (numerical calculations) and also when viewing cards with nature scenes. Participants were imaged both before and after receiving an oral dosage of 20 milligrams of MP. The PET FDG scans showed a significant increase in regional brain glucose utilization when subjects performed the cognitive task, but the increases were significantly greater when they did the task while on placebo as opposed to when they did the task while on MP. The increases in brain glucose metabolism induced by the task were almost 50 percent lower when they were performed with MP than with the placebo. In contrast, when MP was given in a neutral condition (no cognitive task), brain glucose utilization did not change, indicating that its effects are dependent on the context of administration.
“The brain uses glucose as the main source of energy and increases its utilization in proportion to the level of activity. Therefore, the decrease in the amount of glucose required by the brain to perform the cognitive task with MP suggests that one of MP’s mechanisms is to make the brain more efficient,” said Volkow.
The researchers noted that in those individuals who performed well without the stimulant, MP improved performance, whereas in those who performed poorly without medication (who were given a placebo), their performance deteriorated further upon receiving the drug.
“The data suggest that the effects of MP are dependent on the individual’s performance, and since people take these medications in order to improve performance, they need to recognize that for some, performance will deteriorate,” said Volkow.
In addition to deterioration of brain function efficiency, Volkow pointed out that inappropriate usage of these stimulants could lead to addiction. “While MP increased some participants’ ability to focus on a task, use of stimulant medications outside of their intended clinical applications could result not only in deterioration of performance, but also in addiction.”
MP is a central nervous system stimulant. It has effects similar to, but more potent than, caffeine and less potent than amphetamines. It has a notably calming and “focusing” effect on those with ADHD. ADHD consists of a persistent pattern of abnormally high levels of activity, impulsivity, and/or inattention that is more frequently displayed and more severe than is typically observed in individuals with comparable levels of development. Most symptoms improve during adolescence or adulthood, but the disorder can persist or present in adults. Methylphenidate also is occasionally prescribed for treating narcolepsy.
Because stimulant medicines such as MP do have potential for abuse, the U.S. Drug Enforcement Administration (DEA) has placed stringent, Schedule II controls on their manufacture, distribution and prescription. For example, DEA requires special licenses for these activities, and prescription refills are not allowed. Individual states may impose further regulations, such as limiting the number of dosage units per prescription.

Scientific Paper 525: N. Volkow, National Institute of Drug Abuse; F. Telang, Y. Ma, National Institute on Alcohol Abuse and Alcoholism, all in Bethesda, Md.; G. Wang, J. Fowler, J. Logan, C. Wong, K. Pradhan, H. Benveniste, Brookhaven National Lab, Upton, N.Y.; J. Swanson, Univ. of Calif. Irvine, Irvine, Calif., “Methylphenidate Improves the Efficiency of the Human Brain,” SNM’s 55th Annual Meeting, June 14–18, 2008.

For more information: www.snm.org

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Overlay Init